{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:40:31Z","timestamp":1793356831600,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ctro.2026.101290","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:00:16Z","timestamp":1789196416000},"page":"101290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study"],"prefix":"10.1016","volume":"62","author":[{"given":"Sujing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101290_bb0005","article-title":"Comparison of external beam radiation therapy modalities for hepatocellular carcinoma with macrovascular invasion: a meta-analysis and systematic review","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctro.2026.101290_bb0015","doi-asserted-by":"crossref","first-page":"1037145","DOI":"10.3389\/fonc.2022.1037145","article-title":"Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis","volume":"12","author":"He","year":"2022","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.ctro.2026.101290_bb0020","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctro.2026.101290_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021259","article-title":"Recent progress in systemic therapy for advanced hepatocellular carcinoma","volume":"25","author":"Sadagopan","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.ctro.2026.101290_bb0030","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.3390\/curroncol31080315","article-title":"Early changes in alpha-fetoprotein and des-\u03b3-carboxy prothrombin are useful predictors of antitumor response to durvalumab plus tremelimumab therapy for advanced hepatocellular carcinoma","volume":"31","author":"Kuzuya","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctro.2026.101290_bb0035","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.20591","article-title":"Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis","volume":"14","author":"Lin","year":"2026","journal-title":"PeerJ"},{"key":"10.1016\/j.ctro.2026.101290_bb0040","doi-asserted-by":"crossref","first-page":"1449663","DOI":"10.3389\/fimmu.2024.1449663","article-title":"Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101290_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295090","article-title":"Cost-effectiveness analysis of tislelizumab vs sorafenib as the first-line treatment of unresectable hepatocellular carcinoma","volume":"19","author":"Chen","year":"2024","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.ctro.2026.101290_bb0050","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000537966","article-title":"Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.ctro.2026.101290_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000932","article-title":"Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy","volume":"8","author":"Ho","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctro.2026.101290_bb0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jrr\/rraf040","article-title":"Stereotactic body radiotherapy with CyberKnife for liver-confined hepatocellular carcinoma: systematic review and meta-analysis","volume":"66","author":"Abe","year":"2025","journal-title":"J Radiat Res"},{"issue":"3","key":"10.1016\/j.ctro.2026.101290_bb0065","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13246-024-01440-x","article-title":"Dosimetric comparison of proton therapy and CyberKnife in stereotactic body radiation therapy for liver cancers","volume":"47","author":"Shyllon","year":"2024","journal-title":"Phys Eng Sci Med"},{"issue":"8","key":"10.1016\/j.ctro.2026.101290_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.14352","article-title":"Feasibility of patient-specific quality assurance (PSQA) for real-time robotic stereotactic body radiotherapy (SBRT) based on tumor motion traces","volume":"25","author":"Xu","year":"2024","journal-title":"J Appl Clin Med Phys"},{"issue":"3","key":"10.1016\/j.ctro.2026.101290_bb0075","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1021\/acs.jmedchem.3c01785","article-title":"Simultaneous activation of immunogenic cell death and cGAS-STING pathway by liver- and mitochondria-targeted gold(I) complexes for chemoimmunotherapy of hepatocellular carcinoma","volume":"67","author":"Li","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctro.2026.101290_bb0080","doi-asserted-by":"crossref","first-page":"1383000","DOI":"10.3389\/fphar.2024.1383000","article-title":"Harnessing the cGAS-STING pathway to potentiate radiation therapy: current approaches and future directions","volume":"15","author":"Colangelo","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctro.2026.101290_bb0085","article-title":"Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFR\u03b2 complex in hepatocellular carcinoma","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101290_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077903","article-title":"Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial","volume":"14","author":"Zhang","year":"2024","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010050","article-title":"Stereotactic body radiation therapy (SBRT) plus immune checkpoint inhibitors (ICI) in hepatocellular carcinoma and cholangiocarcinoma","volume":"15","author":"Jiang","year":"2022","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.ctro.2026.101290_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184383","article-title":"The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC)","volume":"14","author":"Kimura","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ctro.2026.101290_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"7624","key":"10.1016\/j.ctro.2026.101290_bb0110","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ (Clin Res Ed)"},{"issue":"3","key":"10.1016\/j.ctro.2026.101290_bb0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","article-title":"Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig Dis"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"36","key":"10.1016\/j.ctro.2026.101290_bb0125","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2026.101290_bb0130","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0135","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2020","journal-title":"Actas Dermosifiliogr"},{"issue":"3 Suppl","key":"10.1016\/j.ctro.2026.101290_bb0140","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101290_bb0145","series-title":"Matched sampling for causal effects","first-page":"170","article-title":"The central role of the propensity score in observational studies for causal effects","author":"Rosenbaum","year":"2006"},{"issue":"6","key":"10.1016\/j.ctro.2026.101290_bb0150","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101290_bb0155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jclinepi.2014.08.011","article-title":"Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review","volume":"68","author":"Ali","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"23","key":"10.1016\/j.ctro.2026.101290_bb0160","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.23.01462","article-title":"Patient-reported outcomes from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0165","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41392-023-01604-3","article-title":"Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-025-02717-5","article-title":"Magnetic resonance imaging-guided radiotherapy for portal vein tumor thrombus in hepatocellular carcinoma: outcomes and prognostic factors","volume":"20","author":"Lee","year":"2025","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","article-title":"SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101290_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ctro.2026.101290_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040959","article-title":"Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy","volume":"20","author":"Rapoport","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.ctro.2026.101290_bb0190","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS-STING pathway in cancer biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0205","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s12672-025-02914-4","article-title":"Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma","volume":"16","author":"Xu","year":"2025","journal-title":"Discov Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101290_bb0210","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/hep.32023","article-title":"Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma","volume":"74","author":"Torrens","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0215","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2610526","article-title":"Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma","volume":"27","author":"Liu","year":"2026","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"10.1016\/j.ctro.2026.101290_bb0220","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000209","article-title":"Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma","volume":"7","author":"Yamada","year":"2023","journal-title":"Hepatol Commun"},{"issue":"10","key":"10.1016\/j.ctro.2026.101290_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005248","article-title":"Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination","volume":"10","author":"van der Woude","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctro.2026.101290_bb0230","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/1754-9485.13020","article-title":"Factors affecting target motion in stereotactic body radiotherapy of liver cancer using CyberKnife","volume":"64","author":"Lo","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"9","key":"10.1016\/j.ctro.2026.101290_bb0235","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf203","article-title":"Incidence and risk of hypertension and proteinuria in cancer patients treated with lenvatinib: a systematic review and meta-analysis","volume":"30","author":"Shibutani","year":"2025","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ctro.2026.101290_bb0240","article-title":"Systematic meta-analysis of the toxicities and side effects of the targeted drug lenvatinib","volume":"58","author":"Liu","year":"2026","journal-title":"Ann Med"},{"key":"10.1016\/j.ctro.2026.101290_bb0245","doi-asserted-by":"crossref","first-page":"1596842","DOI":"10.3389\/fimmu.2025.1596842","article-title":"Post-marketing safety concerns with tislelizumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:05:30Z","timestamp":1793354730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":49,"alternative-id":["S2405630826001850"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101290","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101290"}}